Female Sexual Dysfunction Treatment Market Size Report, 2032

Female Sexual Dysfunction Treatment Market – By Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy), Disease (Dyspareunia, HSDD), Route of Administration (Oral, Parenteral, Topical), Distribution Channel – Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp;Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp;Research design

1.2.1&nbsp;&nbsp;&nbsp;Research approach

1.2.2&nbsp;&nbsp;&nbsp;Data collection methods

1.3&nbsp;&nbsp;&nbsp;Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp;Base year calculation

1.3.2&nbsp;&nbsp;&nbsp;Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp;Forecast model

1.5&nbsp;&nbsp;&nbsp;Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp;Primary sources

1.5.2&nbsp;&nbsp;&nbsp;Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp;Industry 360° synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp;Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp;Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp;Growth drivers

3.2.2&nbsp;&nbsp;&nbsp;Increasing awareness regarding female sexual health issues

3.2.3&nbsp;&nbsp;&nbsp;Growing focus towards women&#39;s health

3.2.4&nbsp;&nbsp;&nbsp;Rising research &amp; development activities

3.2.5&nbsp;&nbsp;&nbsp;Increasing advancements in medical technology

3.2.6&nbsp;&nbsp;&nbsp;Industry pitfalls &amp; challenges

3.2.7&nbsp;&nbsp;&nbsp;Societal stigma and taboos associated with female sexual health

3.2.8&nbsp;&nbsp;&nbsp;High treatment costs

3.3&nbsp;&nbsp;&nbsp;Growth potential analysis

3.4&nbsp;&nbsp;&nbsp;Regulatory landscape

3.5&nbsp;&nbsp;&nbsp;Technological landscape

3.6&nbsp;&nbsp;&nbsp;Porter&#39;s analysis

3.7&nbsp;&nbsp;&nbsp;PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.4&nbsp;&nbsp;&nbsp; Strategy outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp;Key trends

5.2&nbsp;&nbsp;&nbsp;Flibanserin

5.3&nbsp;&nbsp;&nbsp;Bremelanotide

5.4&nbsp;&nbsp;&nbsp;Ospemifene

5.5&nbsp;&nbsp;&nbsp;Estrogen therapy

5.6&nbsp;&nbsp;&nbsp;Other drugs

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp;Key trends

6.2&nbsp;&nbsp;&nbsp;Dyspareunia

6.3&nbsp;&nbsp;&nbsp;Hypoactive sexual desire disorder (HSDD)

6.4&nbsp;&nbsp;&nbsp;Other diseases

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp;Key trends

7.2&nbsp;&nbsp;&nbsp;Oral

7.3&nbsp;&nbsp;&nbsp;Parenteral

7.4&nbsp;&nbsp;&nbsp;Topical

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp;Key trends

8.2&nbsp;&nbsp;&nbsp;Hospital pharmacies

8.3&nbsp;&nbsp;&nbsp;Retail pharmacies

8.4&nbsp;&nbsp;&nbsp;Online pharmacies

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp;Key trends

9.2&nbsp;&nbsp;&nbsp;North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp;Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp;Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp;Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp;Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.2&nbsp;&nbsp;&nbsp; South Africa

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles 

10.1&nbsp;&nbsp;&nbsp; Apricus Biosciences, Inc.

10.2&nbsp;&nbsp;&nbsp; Cipla Limited

10.3&nbsp;&nbsp;&nbsp; Freya Pharma Solutions

10.4&nbsp;&nbsp;&nbsp; GSK plc

10.5&nbsp;&nbsp;&nbsp; Lawley Pharmaceuticals Pty Ltd.

10.6&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

10.7&nbsp;&nbsp;&nbsp; Millicent Pharma Limited

10.8&nbsp;&nbsp;&nbsp; Novo Nordisk

10.9&nbsp;&nbsp;&nbsp; Pfizer, Inc.

10.10&nbsp;&nbsp;&nbsp;Sprout Pharmaceuticals, Inc 
&nbsp;

Female Sexual Dysfunction Treatment Market

Get a free sample of this report